Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
1561 studies found for:    Farber's Disease

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Recruiting Biomarker for Farber Disease
Conditions: Farber's Lipogranulomatosis;   Ceramidase Deficiency;   Farber Disease;   Acid Ceramidase Deficiency;   AC Deficiency
Intervention:
2 Completed Mantle Irradiation for Hodgkin's Disease
Condition: Hodgkin's Disease
Intervention: Procedure: Mantle irradiation
3 Completed Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease
Conditions: Breast Cancer;   Hodgkin's Disease
Interventions: Procedure: breast MRI;   Procedure: Mammogram
4 Completed
Has Results 		Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Condition: Hematologic Malignancies
Interventions: Drug: Bortezomib (Velcade);   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: blood stem cell transplantation
5 Completed Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
Conditions: Hodgkin's Disease;   Breast Cancer
Intervention: Drug: Tamoxifen
6 Completed Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Conditions: Acute Myelogenous Leukemia;   Graft Versus Host Disease;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndromes;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease
Interventions: Drug: sirolimus;   Drug: tacrolimus
7 Completed Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Rituximab
8 Terminated Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease
Condition: Lung Cancer
Intervention: Procedure: chest computed tomography scan
9 Active, not recruiting Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation
Condition: Hodgkin's Disease
Intervention: Procedure: Echocardiogram Stress Test
10 Completed Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
Conditions: Hematologic Malignancies;   Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease
Interventions: Drug: Sirolimus;   Drug: Tacrolimus
11 Unknown † Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease
Condition: Graft Versus Host Disease
Interventions: Biological: daclizumab;   Drug: methylprednisolone
12 Completed Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
Conditions: Graft Versus Host Disease;   Hematologic Malignancies
Interventions: Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Stem Cell Transplantation
13 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
14 Recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
15 Recruiting A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Graft-versus-host-disease
Interventions: Procedure: Extracorporeal Photopheresis (ECP);   Drug: Interleukin-2
16 Completed
Has Results 		Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation
Conditions: Graft Versus Host Disease;   GVHD
Interventions: Drug: tacrolimus;   Drug: sirolimus;   Drug: fludarabine;   Drug: busulfex
17 Completed
Has Results 		Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
Conditions: Hemoglobinopathies;   Sickle Cell Disease;   Thalassemia
Interventions: Drug: Busulfex;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Stem Cell Transfusion
18 Recruiting Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease
Condition: Chronic Versus Graft Host Disease
Intervention: Drug: Interleukin-2
19 Unknown † Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation
Condition: Veno-Occlusive Disease
Intervention: Drug: defibrotide
20 Active, not recruiting
Has Results 		Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
Condition: Graft Versus Host Disease
Intervention: Drug: Interleukin-2
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years